Literature DB >> 3729313

Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans.

K L Black, J T Hoff, J E McGillicuddy, S S Gebarski.   

Abstract

Leukotrienes are pharmacologically active compounds that promote vascular permeability. In this study we sought to determine whether tissue leukotriene-like immunoreactivity was increased in intracranial tumors associated with peritumoral edema. In 20 patients undergoing craniotomy tissue specimens were immediately frozen after removal and tissue leukotriene C4 levels were determined by radioimmunoassay. An index of peritumoral edema was estimated from preoperative contrast-enhanced computed tomographic scans. There was a significant correlation between brain edema and tissue leukotriene levels (p less than 0.003). Metastatic tumors (n = 8) had the highest leukotriene C4 level at 13.8 +/- 8.5 pg/mg tissue (mean +/- SE) and the highest index of edema 5.7 +/- 1.8. The mean leukotriene C4 level in the gliomas (n = 5) was 6.2 +/- 2.3 pg/mg tissue and the edema index was 2.1 +/- 0.6. There was no edema and no neoplasm in the temporal lobes removed for seizure (n = 2), and their level of leukotriene C4 was 0.4 +/- 0.1 pg/mg tissue. The formation of leukotriene C4 is stimulated by intracranial tumors. Leukotrienes increase blood-brain barrier permeability and may be important in the formation of vasogenic edema surrounding tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729313     DOI: 10.1002/ana.410190613

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

1.  Reversion of phenotype of endothelial cells in brain tissue around glioblastomas.

Authors:  R Vaz; N Borges; A Sarmento; I Azevedo
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 2.  Blood-brain barrier and new approaches to brain drug delivery.

Authors:  W M Pardridge; R J Boado; K L Black; P A Cancilla
Journal:  West J Med       Date:  1992-03

3.  The contribution of arachidonic acid to the aetiology and pathophysiology of focal brain oedema; studies using an infusion oedema model.

Authors:  I R Whittle; I R Piper; J D Miller
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

Review 4.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

Review 5.  Pharmacological blood-brain barrier modification for selective drug delivery.

Authors:  T F Cloughesy; K L Black
Journal:  J Neurooncol       Date:  1995-11       Impact factor: 4.130

Review 6.  Corticosteroid-use in primary and secondary brain tumour patients: a review.

Authors:  Richella Ryan; Sara Booth; Stephen Price
Journal:  J Neurooncol       Date:  2011-10-05       Impact factor: 4.130

7.  Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family.

Authors:  R J Boado; W M Pardridge; H V Vinters; K L Black
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

8.  Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats.

Authors:  C C Chio; S J Lin; M T Lin
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Eicosanoid production by brain tumours in vivo--evidence for intracranial compartmentation.

Authors:  V Walker; J D Pickard; P J Smythe; S Perry
Journal:  J Neurooncol       Date:  1991-12       Impact factor: 4.130

10.  Role of KCNMA1 gene in breast cancer invasion and metastasis to brain.

Authors:  Divya Khaitan; Umesh T Sankpal; Babette Weksler; Edward A Meister; Ignacio A Romero; Pierre-Olivier Couraud; Nagendra S Ningaraj
Journal:  BMC Cancer       Date:  2009-07-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.